MA49971A - Vésicules extracellulaires modifiées et leurs utilisations - Google Patents
Vésicules extracellulaires modifiées et leurs utilisationsInfo
- Publication number
- MA49971A MA49971A MA049971A MA49971A MA49971A MA 49971 A MA49971 A MA 49971A MA 049971 A MA049971 A MA 049971A MA 49971 A MA49971 A MA 49971A MA 49971 A MA49971 A MA 49971A
- Authority
- MA
- Morocco
- Prior art keywords
- extracellular vesicles
- modified extracellular
- modified
- vesicles
- extracellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835430P | 2019-04-17 | 2019-04-17 | |
PCT/US2019/033629 WO2020101740A1 (fr) | 2018-11-16 | 2019-05-22 | Vésicules extracellulaires modifiées et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49971A true MA49971A (fr) | 2020-07-01 |
MA49971B1 MA49971B1 (fr) | 2022-01-31 |
Family
ID=70732111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49971A MA49971B1 (fr) | 2019-04-17 | 2019-05-22 | Vésicules extracellulaires modifiées et leurs utilisations |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP4059510A1 (fr) |
JP (2) | JP7538795B2 (fr) |
KR (1) | KR20210098473A (fr) |
CN (1) | CN113286603A (fr) |
AU (1) | AU2019378591A1 (fr) |
BR (1) | BR112021009231A2 (fr) |
CA (1) | CA3119720A1 (fr) |
CL (1) | CL2021001278A1 (fr) |
CY (1) | CY1124897T1 (fr) |
DK (1) | DK3672614T3 (fr) |
EA (1) | EA202191334A1 (fr) |
ES (1) | ES2907967T3 (fr) |
HR (1) | HRP20220020T1 (fr) |
HU (1) | HUE057300T2 (fr) |
IL (1) | IL283167A (fr) |
LT (1) | LT3672614T (fr) |
MA (1) | MA49971B1 (fr) |
MD (1) | MD3672614T2 (fr) |
MX (1) | MX2021005636A (fr) |
PH (1) | PH12021551088A1 (fr) |
PL (1) | PL3672614T3 (fr) |
PT (1) | PT3672614T (fr) |
RS (1) | RS62863B1 (fr) |
SG (1) | SG11202104956QA (fr) |
SI (1) | SI3672614T1 (fr) |
TW (1) | TWI846697B (fr) |
WO (1) | WO2020101740A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022531095A (ja) * | 2019-04-17 | 2022-07-06 | コディアック バイオサイエンシーズ, インコーポレイテッド | エキソソーム及びaavの組成物 |
WO2021003445A1 (fr) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations |
JP2022544288A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | CEBP/βを標的とする細胞外小胞-ASO構築物 |
CA3147701A1 (fr) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Vesicules extracellulaires a oligonucleotides antisens ciblant kras |
WO2021030776A1 (fr) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Constructions de vésicules extracellulaires - aso ciblant stat6 |
US20230193274A1 (en) | 2019-08-14 | 2023-06-22 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
US20220395465A1 (en) | 2019-09-25 | 2022-12-15 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
WO2021062058A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Agoniste de sting comprenant des exosomes pour le traitement de troubles neuro-immunologiques |
WO2021062057A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Chargement exogène d'exosomes par lyophilisation |
MX2022003570A (es) | 2019-09-25 | 2022-07-11 | Codiak Biosciences Inc | Composiciones de vesícula extracelular. |
US20230096378A1 (en) | 2020-03-12 | 2023-03-30 | Institute For Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
WO2021184017A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Vésicules extracellulaires pour le traitement de troubles neurologiques |
WO2021184021A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Constructions de vésicules extracellulaires - aso ciblant pmp22 |
WO2021184020A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Méthodes de traitement d'une neuro-inflammation |
JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ, インコーポレイテッド | 治療のための細胞外小胞 |
US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
US20240043494A1 (en) * | 2020-08-07 | 2024-02-08 | Amicus Therapeutics, Inc. | Vesicle Targeting Proteins And Uses Of Same |
CA3193107A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procede de preparation de vesicules extracellulaires |
WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
WO2022178147A1 (fr) | 2021-02-17 | 2022-08-25 | Codiak Biosciences, Inc. | Procédés de chargement de vésicules extracellulaires |
EP4294421A2 (fr) * | 2021-02-17 | 2023-12-27 | Lonza Sales AG | Antagoniste de nlrp3 de vésicule extracellulaire |
IL305873A (en) | 2021-04-01 | 2023-11-01 | Lonza Sales Ag | Extracellular vesicle compositions |
CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
US20230381226A1 (en) * | 2022-05-24 | 2023-11-30 | Shiftbio Inc. | Surface-engineered extracellular vesicles and therapeutic uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
SI2254586T1 (sl) | 2008-02-22 | 2015-07-31 | Agency For Science, Technology And Research (A*Star) | Delci mezenhimske matične celice |
FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
EP3164420A4 (fr) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Conjugués ciblés, particules et préparations associées |
US10501733B2 (en) * | 2015-02-27 | 2019-12-10 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
AU2016381513A1 (en) | 2015-12-30 | 2018-07-19 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
WO2018039119A1 (fr) * | 2016-08-22 | 2018-03-01 | Codiak Biosciences, Inc. | Procédés de suppression de l'administration d'exosomes vers le foie et la rate |
WO2018112154A1 (fr) * | 2016-12-15 | 2018-06-21 | Codiak Biosciences, Inc. | Procédés de mesure d'exosomes à l'aide d'une fluorescence intrinsèque |
CN111212632B (zh) | 2017-08-25 | 2024-04-16 | 隆萨销售股份公司 | 使用膜蛋白制备治疗性外来体 |
AU2018367670A1 (en) * | 2017-11-17 | 2020-05-07 | Lonza Sales Ag | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
WO2020041720A1 (fr) * | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
-
2019
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/fr unknown
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-22 CA CA3119720A patent/CA3119720A1/fr active Pending
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro unknown
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/zh active Pending
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/fr active Pending
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 JP JP2021526563A patent/JP7538795B2/ja active Active
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko active Search and Examination
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/fr active Active
- 2019-05-23 TW TW108117910A patent/TWI846697B/zh active
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
-
2024
- 2024-05-10 JP JP2024077013A patent/JP2024097929A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI846697B (zh) | 2024-07-01 |
MD3672614T2 (ro) | 2022-04-30 |
WO2020101740A9 (fr) | 2021-06-10 |
IL283167A (en) | 2021-06-30 |
LT3672614T (lt) | 2022-04-11 |
BR112021009231A2 (pt) | 2021-08-10 |
TW202038993A (zh) | 2020-11-01 |
ES2907967T3 (es) | 2022-04-27 |
PH12021551088A1 (en) | 2022-01-03 |
CY1124897T1 (el) | 2023-01-05 |
CL2021001278A1 (es) | 2022-03-11 |
SI3672614T1 (sl) | 2022-04-29 |
DK3672614T3 (da) | 2022-01-10 |
HRP20220020T1 (hr) | 2022-04-01 |
CN113286603A (zh) | 2021-08-20 |
RS62863B1 (sr) | 2022-02-28 |
WO2020101740A1 (fr) | 2020-05-22 |
PL3672614T3 (pl) | 2022-03-07 |
EP3672614B1 (fr) | 2021-10-06 |
SG11202104956QA (en) | 2021-06-29 |
AU2019378591A1 (en) | 2021-06-17 |
KR20210098473A (ko) | 2021-08-10 |
PT3672614T (pt) | 2022-02-11 |
MA49971B1 (fr) | 2022-01-31 |
EP3672614A1 (fr) | 2020-07-01 |
CA3119720A1 (fr) | 2020-05-22 |
EP4059510A1 (fr) | 2022-09-21 |
EA202191334A1 (ru) | 2022-02-10 |
JP7538795B2 (ja) | 2024-08-22 |
JP2022513049A (ja) | 2022-02-07 |
MX2021005636A (es) | 2021-07-06 |
JP2024097929A (ja) | 2024-07-19 |
HUE057300T2 (hu) | 2022-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49971A (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
FR24C1023I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
MA52365A (fr) | Composés et leurs utilisations | |
MA46945A (fr) | Exopolysaccharides et leurs utilisations |